Combination therapy with CpG oligodeoxynucleotide and imatinib can reverse the drug resistance when applied alone through promoting BAX activation and overcoming BCR-ABL1-independent PI3K/AKT activation.

Ling Bai,Wei Chen,Wei Li,Lei Zhou,Chao Niu,Jingtao Chen,Wei Han,Jiuwei Cui

Combination therapy with CpG oligodeoxynucleotide and imatinib can reverse the drug resistance when applied alone through promoting BAX activation and overcoming BCR-ABL1-independent PI3K/AKT activation.

2019

Ling Bai
Wei Chen
Wei Li
Lei Zhou
Chao Niu
Jingtao Chen
Wei Han
Jiuwei Cui

e18502Background: Philadelphia chromosome is an independent prognostic factor in B-cell acute lymphoblastic leukemia (B-ALL). Due to the emergence of TKIs resistance such as imatinib, new methods a...

Keywords:

Drug resistance
breakpoint cluster region
PI3K/AKT/mTOR pathway
Combination therapy
Cancer research
Pathology
CpG Oligodeoxynucleotide
Imatinib
ABL
Medicine
Philadelphia chromosome
Protein kinase B
bcr abl1

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations